

Attention-Deficit / Hyperactivity Disorder (ADHD)-Market Insights, Epidemiology and Market Forecast 2028

https://marketpublishers.com/r/A09F2F9C3AFEN.html

Date: June 2019

Pages: 98

Price: US\$ 5,980.00 (Single User License)

ID: A09F2F9C3AFEN

Abstracts

REPORT SUMMARY

'Attention-Deficit / Hyperactivity Disorder (ADHD)- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?
United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 2016-2028

Attention-Deficit / Hyperactivity Disorder (ADHD) Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Attention-Deficit / Hyperactivity Disorder (ADHD)in the US, Europe, and Japan are also provided in the report.

Attention-Deficit / Hyperactivity Disorder (ADHD) Epidemiology



This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Attention-Deficit / Hyperactivity Disorder (ADHD) Product Profiles & Analysis
This part of the Attention-Deficit / Hyperactivity Disorder (ADHD) report encloses the
detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It
provides the key cross competition which evaluates the drugs on several parameters
including, safety & efficacy results, mechanism of action, route, launch dates and
designations. This section also covers the market intelligence and tracking of latest
happenings, agreements and collaborations, approvals, patent details and other major
breakthroughs.

Attention-Deficit / Hyperactivity Disorder (ADHD) Market Outlook

The Attention-Deficit / Hyperactivity Disorder (ADHD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Attention-Deficit / Hyperactivity Disorder (ADHD) Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or
will be launched in the market during the study period from 2016-2028. The analysis
covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This information also helps in understanding the drugs with the most rapid uptake and
the reasons behind the maximal use of new drugs. It provides the comparison of the
drugs on the basis of market share and size. This analysis helps in investigating factors
important in market uptake and in making financial as well as regulatory decisions.

Attention-Deficit / Hyperactivity Disorder (ADHD) Report Insights
Patient Population in Attention-Deficit / Hyperactivity Disorder (ADHD)



Therapeutic Approaches in Attention-Deficit / Hyperactivity Disorder (ADHD)
Attention-Deficit / Hyperactivity Disorder (ADHD) Pipeline Analysis
Attention-Deficit / Hyperactivity Disorder (ADHD) Market Size and Trends
Attention-Deficit / Hyperactivity Disorder (ADHD) Market Opportunities
Impact of upcoming Therapies in Attention-Deficit / Hyperactivity Disorder (ADHD)

Attention-Deficit / Hyperactivity Disorder (ADHD) Report Key Strengths
10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Attention-Deficit / Hyperactivity Disorder (ADHD) Report Assessment
Current Treatment Practices in Attention-Deficit / Hyperactivity Disorder (ADHD)
Unmet Needs in Attention-Deficit / Hyperactivity Disorder (ADHD)
Detailed Attention-Deficit / Hyperactivity Disorder (ADHD) Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Attention-Deficit / Hyperactivity Disorder (ADHD) market Organize sales and marketing efforts by identifying the best opportunities for Attention-Deficit / Hyperactivity Disorder (ADHD) market

To understand the future market competition in the Attention-Deficit / Hyperactivity Disorder (ADHD) market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Contents

1 KEY INSIGHTS

2 ATTENTION-DEFICIT / HYPERACTIVITY DISORDER (ADHD) MARKET OVERVIEW AT A GLANCE

- 2.1 Market Share (%) Distribution of Attention-Deficit / Hyperactivity Disorder (ADHD) in 2018
- 2.2 Market Share (%) Distribution of Attention-Deficit / Hyperactivity Disorder (ADHD) in 2028

3 ATTENTION-DEFICIT / HYPERACTIVITY DISORDER (ADHD): DISEASE BACKGROUND AND OVERVIEW

- 3.1 Introduction
- 3.2 Symptoms
- 3.3 Etiology
- 3.4 Risk Factor
- 3.5 Pathophysiology
- 3.6 Diagnosis
- 3.7 Treatment

4 EPIDEMIOLOGY AND PATIENT POPULATION

- 4.1. Key Findings
- 4.2. Total Prevalent/ Incident Patient Population of Attention-Deficit / Hyperactivity Disorder (ADHD) in 7MM
- 4.3. Total Prevalent Patient Population of Attention-Deficit / Hyperactivity Disorder (ADHD) in 7MM By Countries

5 EPIDEMIOLOGY OF ATTENTION-DEFICIT / HYPERACTIVITY DISORDER (ADHD) BY COUNTRIES (2016-2028)

- 5.1 United States- Epidemiology (2016-2028)
 - 5.1.1 Assumptions and Rationale
- 5.1.2 Prevalent/Incident Cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the United States
 - 5.1.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in



the United States

- 5.1.4 Sex- Specific Cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the United States
- 5.1.5 Diagnosed Cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the United States
- 5.1.6 Treatable Cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the United States
- 5.2 EU5 Countries
 - 5.2.1 Germany
 - 5.2.1.1 Assumptions and Rationale
- 5.2.1.2 Prevalent/Incident Cases of the of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Germany
- 5.2.1.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Germany
- 5.2.1.4 Sex- Specific Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Germany
- 5.2.1.5 Diagnosed Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Germany
 - 5.2.1.6 Treatable Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD)
 - 5.2.2 France
 - 5.2.2.1 Assumptions and Rationale
- 5.2.2.2 Prevalent/Incident Cases of the of Attention-Deficit / Hyperactivity Disorder (ADHD) in the France
- 5.2.2.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the France
- 5.2.2.4 Sex- Specific Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the France
- 5.2.2.5 Diagnosed Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the France
 - 5.2.2.6 Treatable Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) 5.2.3 Italy
 - 5.2.3.1 Assumptions and Rationale
- 5.2.3.2 Prevalent/Incident Cases of the of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Italy
- 5.2.3.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Italy
- 5.2.3.4 Sex- Specific Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Italy
 - 5.2.3.5 Diagnosed Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in



the Italy

- 5.2.3.6 Treatable Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD)
- 5.2.4 Spain
 - 5.2.4.1 Assumptions and Rationale
- 5.2.4.2 Prevalent/Incident Cases of the of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Spain
- 5.2.4.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Spain
- 5.2.4.4 Sex- Specific Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Spain
- 5.2.4.5 Diagnosed Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Spain
 - 5.2.4.6 Treatable Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD)
 - 5.2.5 United Kingdom
 - 5.2.5.1 Assumptions and Rationale
- 5.2.5.2 Prevalent/Incident Cases of the of Attention-Deficit / Hyperactivity Disorder (ADHD) in the United Kingdom
- 5.2.5.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the United Kingdom
- 5.2.5.4 Sex- Specific Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the United Kingdom
- 5.2.5.5 Diagnosed Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the United Kingdom
- 5.2.5.6 Treatable Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD)5.3 Japan
 - 5.3.1 Assumptions and Rationale
- 5.3.2 Prevalent/Incident Cases of the of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Japan
- 5.3.3 Sub-Type Specific cases of Attention-Deficit / Hyperactivity Disorder (ADHD) in the Japan
- 5.3.4 Sex- Specific Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Japan
- 5.3.5 Diagnosed Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD) in the Japan
 - 5.3.6 Treatable Cases of the Attention-Deficit / Hyperactivity Disorder (ADHD)

6 CURRENT TREATMENT & MEDICAL PRACTICES

6.1 Treatment Algorithm



6.2 Treatment Guidelines

7 UNMET NEEDS

8 MARKETED PRODUCT

- 8.1 Drug A: Company
 - 8.1.1 Drug Description
 - 8.1.2 Mechanism of Action
 - 8.1.3 Clinical Trials Details
 - 8.1.4 Advantages & Disadvantages
 - 8.1.5 Safety and Efficacy
 - 8.1.6 Product Profile
- 8.2 Drug B: Company
 - 8.2.1 Drug Description
 - 8.2.2 Mechanism of Action
 - 8.2.3 Clinical Trials Details
 - 8.2.4 Advantages & Disadvantages
 - 8.2.5 Safety and Efficacy
 - 8.2.6 Product Profile
- 8.3 Drug C: Company
 - 8.3.1 Drug Description
 - 8.3.2 Mechanism of Action
 - 8.3.3 Clinical Trials Details
 - 8.3.4 Advantages & Disadvantages
 - 8.3.5 Safety and Efficacy
 - 8.3.6 Product Profile
- 8.4 Drug D: Company
 - 8.4.1 Drug Description
 - 8.4.2 Mechanism of Action
 - 8.4.3 Clinical Trials Details
 - 8.4.4 Advantages & Disadvantages
 - 8.4.5 Safety and Efficacy
 - 8.4.6 Product Profile
- 8.5 Drug E: Company
 - 8.5.1 Drug Description
 - 8.5.2 Mechanism of Action
 - 8.5.3 Clinical Trials Details
 - 8.5.4 Advantages & Disadvantages



- 8.5.5 Safety and Efficacy
- 8.5.6 Product Profile
- 8.6 : Company
 - 8.6.1 Drug Description
 - 8.6.2 Mechanism of Action
 - 8.6.3 Clinical Trials Details
 - 8.6.4 Advantages & Disadvantages
 - 8.6.5 Safety and Efficacy
- 8.6.6 Product Profile
- 8.7 : Company
 - 8.7.1 Drug Description
 - 8.7.2 Mechanism of Action
 - 8.7.3 Clinical Trials Details
 - 8.7.4 Advantages & Disadvantages
 - 8.7.5 Safety and Efficacy
 - 8.7.6 Product Profile
- 8.8 : Company
 - 8.8.1 Drug Description
 - 8.8.2 Mechanism of Action
 - 8.8.3 Clinical Trials Details
 - 8.8.4 Advantages & Disadvantages
 - 8.8.5 Safety and Efficacy
 - 8.8.6 Product Profile

9 EMERGING DRUGS

- 9.1 Key Cross Competition
- 9.2 Emerging company
 - 9.2.1 Emerging Drug A: Company
 - 9.2.1.1 Other Development Activities
 - 9.2.1.2 Clinical Development
 - 9.2.1.3 Clinical Trials Information
 - 9.2.1.4 Safety and Efficacy
 - 9.2.1.5 Advantages and Disadvantages
 - 9.2.1.6 Product Profile
 - 9.2.2 Emerging Drug B: Company
 - 9.2.2.1 Other Development Activities
 - 9.2.2.2 Clinical Development
 - 9.2.2.3 Clinical Trials Information



- 9.2.2.4 Safety and Efficacy
- 9.2.2.5 Advantages and Disadvantages
- 9.2.2.6 Product Profile
- 9.2.3 Emerging Drug C: Company
 - 9.2.3.1 Other Development Activities
 - 9.2.3.2 Clinical Development
 - 9.2.3.3 Clinical Trials Information
 - 9.2.3.4 Safety and Efficacy
 - 9.2.3.5 Advantages and Disadvantages
 - 9.2.3.6 Product Profile
- 9.2.4 Emerging Drug D: Company
- 9.2.4.1 Other Development Activities
- 9.2.4.2 Clinical Development
- 9.2.4.3 Clinical Trials Information
- 9.2.4.4 Safety and Efficacy
- 9.2.4.5 Advantages and Disadvantages
- 9.2.4.6 Product Profile
- 9.2.5 Emerging Drug E: Company
- 9.2.5.1 Other Development Activities
- 9.2.5.2 Clinical Development
- 9.2.5.3 Clinical Trials Information
- 9.2.5.4 Safety and Efficacy
- 9.2.5.5 Advantages and Disadvantages
- 9.2.5.6 Product Profile

10 7MM MARKET ANALYSIS

- 10.1 7MM Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD)
- 10.2 7MM Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD)
- 10.3 7MM Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products

11 THE UNITED STATES MARKET OUTLOOK

- 11.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in United States
- 11.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in United States
- 11.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in United States



11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 COUNTRIES MARKET OUTLOOK

- 12.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in EU5
- 12.2 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Germany
 - 12.2.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Germany
- 12.2.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in Germany
- 12.2.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in Germany
 - 12.2.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.3 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in France
- 12.3.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in France
- 12.3.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in France
- 12.3.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in France
 - 12.3.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.4 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Italy
- 12.4.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Italy
- 12.4.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in Italy
- 12.4.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in Italy
 - 12.4.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.5 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Spain
 - 12.5.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Spain
- 12.5.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in Spain
- 12.5.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in Spain
 - 12.5.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.6 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in United Kingdom
- 12.6.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in United Kingdom
- 12.6.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in United Kingdom
 - 12.6.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in



United Kingdom

12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 THE JAPAN MARKET OUTLOOK

- 13.1 Market Size of Attention-Deficit / Hyperactivity Disorder (ADHD) in Japan
- 13.2 Percentage Share of Drugs Marketed for Attention-Deficit / Hyperactivity Disorder (ADHD) in Japan
- 13.3 Market Sales of Attention-Deficit / Hyperactivity Disorder (ADHD) by Products in Japan
- 13.4 Analysis of Upcoming Therapies and Impact on the Market

14 COST ANALYSIS OF ATTENTION-DEFICIT / HYPERACTIVITY DISORDER (ADHD)

15 GENERIC COMPETITION IN ATTENTION-DEFICIT / HYPERACTIVITY DISORDER (ADHD) MARKET

16 MARKET DRIVERS

17 MARKET BARRIERS

18 REPORT METHODOLOGY

- 18.1 Methodology/Research Approach
- 18.2 Data Source
 - 18.2.1 Secondary Sources
 - 18.2.2 Primary Sources



I would like to order

Product name: Attention-Deficit / Hyperactivity Disorder (ADHD)- Market Insights, Epidemiology and

Market Forecast 2028

Product link: https://marketpublishers.com/r/A09F2F9C3AFEN.html

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A09F2F9C3AFEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

